Evaluation of Fully Automated MAGLUMI SARS-CoV-2 IgM/IgG Chemiluminescence Immunoassay at the Point That the Immune Response to the Disease Has Not Been Established Yet

Ayse Istanbullu Tosun & Filiz Yarimcan^*

Department of Medical Microbiology, Istanbul Medipol University, Turkey

Dr. Filiz Yarimcan, Department of Medical Microbiology, Istanbul Medipol University, Turkey.

Keywords: COVID-19; SARS-CoV-2; Sensitivity; Specificity; CLIA

Abstract

Purpose
There is a need for serological tests to diagnose and manage epidemiologically COVID-19. Several high throughput technologies developed SARS-CoV-2 antibody kits, the performance of which has not been studied yet. We aimed to evaluate MAGLUMI SARS-CoV-2 IgM/IgG Chemiluminescent Immunoassay (Snibe, China).
Method
We tested sera of confirmed COVID-19 cases (n=39) and control samples of healthy subjects (n=56). The samples were collected at 39.2 ± 15.2 (range, 14 to 56) days after the symptom onset.

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).